INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

ADMA Biologics, Inc. (NASDAQ: ADMA) investors who purchased or acquired publicly traded securities between August 9, 2024 and March 25, 2026, inclusive, have until Monday, August 10, 2026, to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. The lawsuit charges ADMA Biologics and certain of its top executive officers with violations of the Securities Exchange Act of 1934. ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) ADMA Biologics engaged in an undisclosed related party transaction; (ii) ADMA Biologics used channel stuffing to create an appearance of revenue; and (iii) ADMA Biologics lacked adequate internal controls. On March 24, 2026, Culper Research issued a report asserting that ADMA Biologics' reported growth was a fiction driven by channel stuffing and an undisclosed related party distributor, and that had payment terms remained steady, the company would have reported a 3% year-over-year revenue decline in 2025. On this news, the stock price declined over 16%. On March 25, 2026, ADMA Biologics issued a press release stating the report was premised on speculative assertions and contained misleading, false, and inaccurate statements. On March 26, 2026, an article reported that Cantor Fitzgerald downgraded ADMA Biologics to Neutral from Overweight due to short report concerns, and that investors expressed disappointment in the company's response. On this news, the stock price fell more than 13%.